Related Experiment Video

Updated: Jul 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Eptifibatide in percutaneous coronary intervention. A review

J P Dery1, J C O'Shea, J E Tcheng

  • 1Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA.

Minerva Cardioangiologica
|October 18, 2002
PubMed

Insights

Glycoprotein (GP) IIb-IIIa inhibitors, like eptifibatide, significantly reduce ischemic complications in patients undergoing percutaneous coronary intervention (PCI). These findings highlight the importance of GP IIb-IIIa inhibitors in PCI treatment strategies.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Percutaneous coronary angioplasty and stenting (PCI) is a common treatment for coronary artery disease.
  • Glycoprotein (GP) IIb-IIIa inhibitors are a class of drugs proven to reduce ischemic complications during PCI.

Purpose of the Study:

  • To review the efficacy of eptifibatide, a GP IIb-IIIa inhibitor, in patients undergoing PCI.
  • To emphasize the importance of GP IIb-IIIa inhibitors in PCI.

Main Methods:

  • Review of the IMPACT II and ESPRIT clinical trials.
  • Analysis of ischemic complication rates in patients treated with eptifibatide versus placebo.

Main Results:

  • Eptifibatide significantly reduced ischemic complications in patients undergoing PCI compared to placebo.
  • Landmark trials demonstrate the effectiveness of eptifibatide.

Conclusions:

  • GP IIb-IIIa inhibitors, including eptifibatide, are crucial for managing ischemic risk in PCI.
  • Consideration of GP IIb-IIIa inhibitors should be standard practice for all PCI patients.

More Related Videos

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...